Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF

The use of rivaroxaban compared with warfarin was associated with a higher risk of stroke and bleeding in patients with polyvascular disease enrolled in ROCKET AF. Further studies are needed to understand the optimal management of this high-risk population.